GELS (gelteq.com) Multiplikator Forward P/S

Gelteq Limited previously focused on costly prototypes, but is now transitioning toward the commercial licensing of patents. The forward P/S valuation reflects this transformation, where the value 32.60 indicates the current level of market confidence. Business growth relies on gel dosing precision and deals with tech giants, although expansion may be limited by alternative drug delivery methods from major players.

The forward P/S reflects the ratio of Gelteq Limited (GELS) market capitalization to expected revenue, measuring the premium investors are willing to pay for future operational success. In the context of exclusive B2B developments in gel-based drug delivery, the forward P/S value allows for an assessment of how much the market currently prices in the monetization potential of patented encapsulation technologies.